FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS

Area of Science:

• Infectious Diseases
• Immunology
• Bacteriology

Background:

• Intradermal Type I pneumococcus infection in rabbits mimics human lobar pneumonia.
• Disease progression exhibits mathematical characteristics, suggesting a toxic substance accumulation.

Purpose of the Study:

• To investigate therapeutic strategies for pneumococcus infection.
• To evaluate antipneumococcus sera and non-specific therapies.
• To assess immunity development after infection and treatment.

Main Methods:

• Intradermal pneumococcus infection model in rabbits.
• Testing various antipneumococcus sera for therapeutic efficacy.
• Comparison of therapeutic value with mouse-protective value.
• Administration of heterologous and homologous sera for therapy and immunity studies.

Main Results:

• Therapeutic antiserum requirements increase mathematically with disease progression.
• Therapeutic efficacy of antipneumococcus sera does not correlate with mouse-protective values.
• Non-specific therapy causes transient organism clearance from the bloodstream.
• Homologous immune serum confers immunity, while heterologous serum does not.

Conclusions:

• The rabbit model is suitable for standardizing antipneumococcus sera.
• Disease progression is influenced by an unknown toxic substance.
• Homologous serum therapy is crucial for developing lasting immunity.
• Vaccination strategies may be applicable to human pneumonias.